Welcome to our dedicated page for Ikena Oncology news (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology stock.
Ikena Oncology (NASDAQ: IKNA) is a clinical-stage biopharmaceutical company pioneering biomarker-driven therapies targeting cancer's molecular drivers. This page provides investors and researchers with essential updates on IKNA's pipeline progress, strategic partnerships, and scientific advancements in precision oncology.
Access real-time announcements about IKNA's programs, including developments in Hippo pathway inhibitors and RAS signaling research. Our curated news collection features earnings reports, clinical trial milestones, and corporate updates – all critical for evaluating the company's position in targeted cancer therapy.
Key content includes updates on IKNA's precision medicine approach, collaborations with industry leaders, and regulatory filings. Bookmark this page to efficiently track how the company addresses therapeutic resistance mechanisms through its innovative drug candidates.
Ikena Oncology announced new preclinical data on its selective Hippo pathway inhibitor IK-930 at the AACR Annual Meeting in Orlando, FL, from April 14-19, 2023. IK-930 selectively inhibits TEAD1 and demonstrates potential for enhanced antitumor activity without renal toxicity, a common issue with broader TEAD inhibitors. The findings suggest that IK-930 can also combat therapeutic resistance in various cancers, including EGFR and RAS mutant cancers. The drug is designed to improve patient outcomes by selectively targeting oncogenic pathways while minimizing adverse effects. Ongoing Phase 1 trials for IK-930 aim to explore its efficacy in various solid tumors with Hippo pathway mutations.
Ikena Oncology, Inc. (Nasdaq: IKNA) reported strong progress in its oncology pipeline, highlighted by advancements in three key drug candidates. IK-930, a TEAD inhibitor, received Fast Track and Orphan designations and will present initial clinical data in 2H 2023. IK-595, a MEK-RAF complex inhibitor, is on track for IND submission later this year, aiming to address significant unmet needs in RAS mutated cancers. IK-175, an AHR inhibitor, also received Fast Track designation. Financially, the company had $156.9 million in reserves, expected to sustain operations into 2025, despite increasing R&D expenses of $64.3 million for 2022, up from $47.1 million in 2021.
Ikena Oncology (Nasdaq: IKNA) announced the presentation of preclinical data on its MEK-RAF inhibitor, IK-595, at the AACR Special Conference: Targeting RAS in Philadelphia, March 5-8, 2023. IK-595 aims to improve cancer treatment by inhibiting the RAS pathway implicated in many cancer diagnoses. Highlights include IK-595's ability to stabilize the MEK-RAF complex, block MEK phosphorylation in RAS mutant cells, and demonstrate significant anti-tumor efficacy across various cancer models. Ikena plans to submit an IND application for IK-595 in the second half of 2023, targeting RAS mutant cancer subsets that face significant unmet medical needs.
Ikena Oncology (Nasdaq: IKNA) announced that the FDA granted Fast Track designation to IK-175, a novel AHR antagonist, for patients with advanced urothelial carcinoma who have progressed after checkpoint inhibitors. This designation allows Ikena to communicate more frequently with the FDA regarding trial design and increases the likelihood of priority review and accelerated approval. IK-175 is currently in a Phase 1a/b trial, showing promising results for patients with solid tumors. This marks the second Fast Track designation for Ikena, following IK-930 for malignant pleural mesothelioma, underscoring the company's commitment to advancing cancer treatment options.
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology (Nasdaq: IKNA) announced participation in a Targeted Oncology Panel at the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, in Boston, MA. The panel will feature CEO Mark Manfredi on March 7, 2023, from 2:10 PM to 3:10 PM EST. A webcast of the panel will be available for live streaming and archived for 30 days. Ikena focuses on developing differentiated cancer therapies, with lead program IK-930 targeting the Hippo signaling pathway. The company aims to develop the right drugs for the right patients.
Ikena Oncology has announced the appointment of Owen Hughes as the new Chairman of the Board, effective December 15, 2022. Hughes, who brings extensive operational experience from firms like Sail Bio and Cullinan Oncology, replaces Ron Renaud, who transitions to a role at Bain Capital Life Sciences after four years with Ikena. The leadership change is seen as a continuity for Ikena's mission in targeted oncology therapies. Hughes emphasizes his commitment to advancing and growing Ikena's pipeline to redefine the oncology landscape.
Ikena Oncology (Nasdaq: IKNA) has announced the nomination of IK-595 as its first development candidate targeting the RAS pathway, which is involved in numerous cancer diagnoses. IK-595 aims to inhibit the MEK-RAF signaling pathway more effectively than existing treatments, with an IND application planned for submission in late 2023. Ikena is also advancing IK-930, a TEAD inhibitor, in clinical trials. Following a portfolio review, the company will discontinue development of the EP4 antagonist IK-007. Ikena's cash runway has been extended into 2025, bolstering its oncology portfolio.
Ikena Oncology, a targeted oncology company, will present at the Piper Sandler 34th Annual Healthcare Conference in New York, NY, from November 29 to December 1, 2022. Management will provide a corporate overview on November 29 at 12:10 p.m. ET. The presentation will focus on their novel therapies aimed at treating cancer, particularly through their lead program, IK-930, a TEAD inhibitor targeting the Hippo signaling pathway. Investors can access the live webcast on Ikena's website, which will be archived for 90 days.
Ikena Oncology presented promising clinical data regarding IK-175 for treating urothelial carcinoma at the SITC Annual Meeting. In a cohort of 43 patients, the combination with nivolumab resulted in a 20% overall response rate (ORR) and 40% disease control rate (DCR). Notably, IK-175 monotherapy showed a confirmed partial response lasting 14.9 months. The drug was well tolerated, with manageable side effects. This collaboration may significantly enhance treatment options for patients who have exhausted existing therapies, with Bristol Myers Squibb eligible for opt-in by early 2024.
On November 7, 2022, Ikena Oncology (Nasdaq: IKNA) reported its third-quarter financial results, highlighting progress in clinical trials for its AHR antagonist IK-175 and the targeted therapy IK-930. Initial data indicate that IK-175 shows anti-tumor activity and is well-tolerated in heavily pre-treated patients with urothelial carcinoma. The company has $174.4 million in cash, expected to last through mid-2024, despite an operating cash burn of $17.2 million in Q3 2022. Increased research and development expenses reflect expanded activities in their clinical pipeline.
FAQ
What is the current stock price of Ikena Oncology (IKNA)?
What is the market cap of Ikena Oncology (IKNA)?
